UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________

 

FORM 8-K

___________________________

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 15, 2016

___________________________

 

Signal Genetics, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware	001-36483	47-1187261
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

 

 

Signal Genetics, Inc.
5740 Fleet Street
Carlsbad, California	92008
(Address of principal executive offices)	(Zip Code)

   

Registrant's telephone number, including area code: (760) 537-4100

___________________________

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 5.07          Submission of Matters to a Vote of Security Holders.

 

At the 2016 Annual Meeting of Stockholders of Signal Genetics, Inc. (the “Company”), held on June 15, 2016, three proposals were submitted to and approved by the stockholders of the Company. The proposals are described in detail in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on May 9, 2016. The final results for the votes regarding each proposal are set forth below.

 

1. Stockholders elected five directors to the Company’s Board of Directors to hold office for a one-year term until the annual meeting of stockholders in 2017 and until their successors are elected and qualified. The votes regarding this proposal were as follows:

 

		For		Against		Abstained
Bennett S. LeBow		4,298,612		340,259		10,200
Samuel D. Riccitelli		3,541,776		1,047,095		60,200
David A. Gonyer, R. Ph.		3,547,807		990,675		110,589
Douglas A. Schuling		3,550,276		987,306		111,489
Robin L. Smith, M.D.		3,533,671		1,000,442		114,958

 

2. Stockholders ratified the selection of BDO USA, LLP as independent registered public accounting firm for the fiscal year ending December 31, 2016. The votes regarding this proposal were as follows:

 

For		Against		Abstained
6,893,644		1,238,328		145,177

 

3. Stockholders approved the Amendment to the Company’s Certificate of Incorporation Effecting a Reverse Stock Split of the Company’s Common Stock in accordance with a ratio to be determined by the Company’s Board of Directors within a range of one share of Common Stock for every two (2) to twenty (20) shares of Common Stock:

 

For		Against		Abstained
6,470,138		1,721,729		85,282

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

		SIGNAL GENETICS, INC.
		By:	/s/ Tamara A. Seymour
		Name:	Tamara A. Seymour
		Title:	Chief Financial Officer

Date: June 16, 2016